metformin has been researched along with Hyperandrogenism in 145 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Hyperandrogenism: A condition caused by the excessive secretion of ANDROGENS from the ADRENAL CORTEX; the OVARIES; or the TESTES. The clinical significance in males is negligible. In women, the common manifestations are HIRSUTISM and VIRILISM as seen in patients with POLYCYSTIC OVARY SYNDROME and ADRENOCORTICAL HYPERFUNCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "s-PROK1 was analysed using ELISA at gestational week 19 and related to pregnancy complications, fasting insulin levels, homoeostatic model assessment for insulin resistance (HOMA-IR), testosterone, or androstenedione levels, metformin use, PCOS phenotype and hyperandrogenism." | 9.69 | Maternal serum levels of prokineticin-1 related to pregnancy complications and metformin use in women with polycystic ovary syndrome: a post hoc analysis of two prospective, randomised, placebo-controlled trials. ( Hirschberg, AL; Trouva, A; Ujvari, D; Vanky, E, 2023) |
| "To summarize the effects of metformin treatment on markers of hyperandrogenism in patients diagnosed with polycystic ovary syndrome (PCOS)." | 9.41 | Influence of metformin on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials. ( Cândido, AL; Fontes, AFS; Gomes, KB; Reis, FM; Tosatti, JAG, 2023) |
| " While metformin has a mild androgen-lowering effect in non-pregnant women with PCOS, its effects on maternal androgen levels in pregnancy are less well understood." | 9.34 | Sustained Maternal Hyperandrogenism During PCOS Pregnancy Reduced by Metformin in Non-obese Women Carrying a Male Fetus. ( Abbott, D; Andræ, F; Odsæter, IH; Salvesen, Ø; Schmedes, AV; Stridsklev, S; Vanky, E, 2020) |
| "Aim of this study was to evaluate the effect of vitamin D supplementation in obese, insulin resistant and vitamin D deficient PCOS women on biochemical and clinical hyperandrogenism and menstrual irregularity in comparison to effect of metformin or combined metformin plus vitamin D therapy." | 9.22 | The effect of alfacalcidiol and metformin on phenotype manifestations in women with polycystic ovary syndrome - a preliminary study. ( Dravecká, I; Figurová, J; Javorský, M; Lazúrová, I; Petríková, J; Vaľková, M, 2016) |
| "Conclusions on the effect of metformin on circulating anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS) are ambiguous." | 9.20 | Impact of metformin on anti-Müllerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial. ( Ingerslev, HJ; Lauszus, FF; Madsen, HN; Trolle, B; Tørring, N, 2015) |
| " It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone." | 9.19 | In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014) |
| "Hyperandrogenaemia in polycystic ovary syndrome (PCOS) represents a composite of raised serum concentrations of testosterone, androstenedione, dehydroepiandrosterone (DHEA) and DHEA sulphate (DHEAS)." | 9.16 | Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. ( Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T; Smith, KA, 2012) |
| "To assess the impact of metformin and of two different oral contraceptives (OCs) containing cyproterone acetate and drospirenone, on serum anti-Müllerian hormone (AMH) levels, in a cohort of women with polycystic ovary syndrome (PCOS) with hyperandrogenism." | 9.15 | The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. ( Decavalas, G; Diamanti-Kandarakis, E; Georgopoulos, NA; Katsikis, I; Panidis, D; Piouka, A; Saltamavros, AD, 2011) |
| "In LBW-PP girls, early metformin therapy was found to prevent or delay the development of hirsutism, androgen excess, oligomenorrhea, and PCOS more effectively than late metformin." | 9.15 | Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Marcos, MV, 2011) |
| "To evaluate the clinical, endocrine and metabolic effects of metformin and N-acetyl-cysteine (NAC) in patients with polycystic ovary syndrome (PCOS)." | 9.15 | Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. ( Muderris, II; Oner, G, 2011) |
| " Both simvastatin and metformin improved menstrual cyclicity and decreased hirsutism, acne, ovarian volume, body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1." | 9.15 | Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. ( Banaszewska, B; Duleba, AJ; Pawelczyk, L; Spaczynski, RZ, 2011) |
| "Only orlistat reduced both IR and its variability significantly, though all three drugs were effective in reducing hyperandrogenism within the 12-week period of the study." | 9.14 | Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. ( Atkin, SL; Cho, LW; Coady, AM; Keevil, BG; Kilpatrick, ES, 2009) |
| "To evaluate the effect of a short-course pretreatment with metformin on hyperandrogenism, insulin resistance, cervical scores, and pregnancy rates in women with clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS)." | 9.14 | Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. ( Ghaffarpasand, F; Kazerooni, M; Kazerooni, T; Kazerooni, Y; Setoodeh, S, 2009) |
| "To compare the effects of insulin sensitization with metformin to weight reduction by rimonabant on biochemical hyperandrogenaemia and insulin resistance in patients with PCOS." | 9.13 | A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. ( Atkin, SL; Cho, LW; Coady, AM; Kilpatrick, ES; Sathyapalan, T, 2008) |
| "Low-dose flutamide-metformin (Flu-Met) with an oral contraceptive is a therapeutic option for women with hyperinsulinaemic hyperandrogenism." | 9.12 | Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-alpha and the neutrophil/lymphocyte ratio. ( de Zegher, F; Ibáñez, L; Valls, C, 2006) |
| " Much better decrease in the level of testosterone and free androgen index was established in group treated with metformin, while the indices of insulin resistance were better influenced in the group treated with rosiglitazone." | 9.12 | Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. ( Mitkov, M; Pehlivanov, B; Terzieva, D, 2006) |
| "A low-dose combination of flutamide-metformin and ethinylestradiol-drospirenone was recently found to reduce the excess of total and abdominal fat, to diminish the deficit in lean mass, and to attenuate the dysadipocytokinemia of young women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 9.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. ( Cabré, S; De Zegher, F; Ibáñez, L; Valls, C, 2004) |
| "Flutamide (Flu)-metformin (Met) with ethinylestradiol-drospirenone is a combination therapy that reduces the total and abdominal fat excess, diminishes the lean mass deficit, and attenuates the dysadipocytokinemia of young and nonobese women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 9.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. ( de Zegher, F; Ibáñez, L, 2005) |
| " The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment." | 9.11 | Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. ( Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A, 2005) |
| "In adolescents and young women with hyperinsulinaemic hyperandrogenism (n = 118; mean age 16 years, body mass index 22 kg/m(2)), we analysed whether the PCOS-associated rise in leukocyte count is already detectable at young age and, if so, whether such elevation is lowered by metformin, flutamide-metformin, oral contraception (OC), or their combination." | 9.11 | High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception. ( de Zegher, F; Ferrer, A; Ibáñez, L; Jaramillo, AM, 2005) |
| "Most patients with polycystic ovary syndrome (PCOS) have hyperinsulinemia; thus it has been postulated that insulin-lowering drugs, such as metformin, might be a useful long-term choice." | 9.10 | Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. ( De Pergola, G; Lorusso, F; Loverro, G; Mei, L; Nicolardi, V; Selvaggi, L, 2002) |
| "The endocrine-metabolic status of non-obese, young women with polycystic ovary syndrome (PCOS) is normalized more effectively by combined treatment with flutamide and metformin than by either of these drugs in monotherapy." | 9.10 | Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. ( de Zegher, F; Ibáñez, L, 2003) |
| "To evaluate the effects of 12 weeks of metformin therapy on hormonal and clinical indices in polycystic ovary syndrome (PCOS)." | 9.09 | Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. ( Duleba, AJ; Kolodziejczyk, B; Pawelczyk, L; Spaczynski, RZ, 2000) |
| "The use of insulin-sensitising agents, such as metformin, in women with polycystic ovary syndrome (PCOS) who are undergoing ovulation induction or in vitro fertilisation (IVF) cycles has been widely studied." | 8.90 | Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. ( Albuquerque, LE; Andriolo, RB; Costello, MF; Macedo, CR; Tso, LO, 2014) |
| "This article is a review of the literature assessing pregnancy outcomes and the effect of metformin treatment among women with polycystic ovary syndrome (PCOS)." | 8.88 | Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview. ( Awwad, JT; Ghazeeri, GS; Nassar, AH; Younes, Z, 2012) |
| "The use of insulin-sensitising agents, such as metformin, in women with polycystic ovary syndrome (PCOS) who are undergoing ovulation induction or in vitro fertilisation (IVF) cycles has been widely studied." | 8.85 | Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. ( Albuquerque, LE; Andriolo, RB; Costello, MF; Freitas, V; Tso, LO, 2009) |
| "The latest list of reimbursed medicines includes, as a new addition, metformin for the treatment of polycystic ovary syndrome (PCOS), which is extremely important for practicing physicians." | 7.79 | Metformin for polycystic ovary syndrome. ( Milewicz, A, 2013) |
| "We aimed to compare the effects of metformin and metformin-rosuvastatin combination therapies on hyperandrogenism in patients with polycystic ovary syndrome (PCOS)." | 7.78 | Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance. ( Acbay, O; Celik, O, 2012) |
| " We tested the hypothesis that a gene variant in STK11 contributes to variation in insulin sensitivity and metformin efficacy." | 7.76 | A single nucleotide polymorphism in STK11 influences insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Morán, E, 2010) |
| " We sought to characterize patients with biochemical hyperandrogenism in respect of tumor versus non-tumor etiologies, explore possible links between non-tumor hyperandrogenism and metabolic syndrome, and ascertain whether metformin therapy can elicit diagnostic reductions in serum testosterone (T)." | 7.74 | The investigation and management of severe hyperandrogenism pre- and postmenopause: non-tumor disease is strongly associated with metabolic syndrome and typically responds to insulin-sensitization with metformin. ( Advani, A; Al-Ozairi, E; Ball, SG; James, RA; Lim, E; Quinton, R; Vaikkakara, S, 2008) |
| "Hyperinsulinemic hyperandrogenism is the core of polycystic ovary syndrome (PCOS), and, accordingly, low-dose flutamide-metformin proved so far to be a most effective approach to normalize the broad spectrum of PCOS anomalies in nonobese adolescents and young women." | 7.73 | Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in nonobese adolescents and women. ( de Zegher, F; Ibáñez, L, 2006) |
| "To assess the effects of metformin on tissue insulin sensitivity in obese and hyperandrogenic women." | 7.69 | [Effects of metformin on insulin resistance in obese and hyperandrogenic women]. ( Calvillán, M; Castillo, T; López, G; Muñoz, S; Sir, T, 1997) |
| "Metformin treatment was associated with decreases in testosterone, free androgen index, androstenedione, 17-OH progesterone and estradiol levels." | 6.78 | Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus. ( Asenjo, S; Cassorla, F; Codner, E; Eyzaguirre, FC; Iñíguez, G; López, P; Mujica, V; Torrealba, I, 2013) |
| "Simvastatin treatment was superior to metformin alone, whereas a combination of simvastatin and metformin was not significantly superior to simvastatin alone." | 6.74 | Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. ( Banaszewska, B; Duleba, AJ; Pawelczyk, L; Spaczynski, RZ, 2009) |
| "Metformin was then given at a dose of 500 mg three times a day for 8 weeks, after which time the pretreatment study was repeated." | 6.71 | Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. ( Dehghan-Kooshkghazi, M; Kazerooni, T, 2003) |
| "Flutamide-metformin treatment (n = 30) was followed within 3 months by marked decreases in hirsutism score and serum androgens, by a more than 50% increase in insulin sensitivity and by a less atherogenic lipid profile (all P < 0." | 6.71 | Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. ( Amin, R; de Zegher, F; Dunger, D; Ferrer, A; Ibáñez, L; Ong, K, 2003) |
| "Metformin was well tolerated except for one case of flatulence." | 6.69 | Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. ( Bergiele, A; Diamanti-Kandarakis, E; Kouli, C; Tsianateli, T, 1998) |
| "Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2 diabetes mellitus." | 6.45 | Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2009) |
| "Polycystic ovary syndrome is a frequent endocrine disorder often associated with insulin resistance and hyperinsulinaemia which may play a role in hyperandrogenism and anovulation." | 6.42 | [Should infertile women with polycystic ovarian syndrome be treated with metformine?]. ( Basille, C; Bry-Gauillard, H; Cédrin-Durnerin, I; Galey, J; Hugues, JN; Massin, N; Théron-Gérard, L, 2003) |
| "s-PROK1 was analysed using ELISA at gestational week 19 and related to pregnancy complications, fasting insulin levels, homoeostatic model assessment for insulin resistance (HOMA-IR), testosterone, or androstenedione levels, metformin use, PCOS phenotype and hyperandrogenism." | 5.69 | Maternal serum levels of prokineticin-1 related to pregnancy complications and metformin use in women with polycystic ovary syndrome: a post hoc analysis of two prospective, randomised, placebo-controlled trials. ( Hirschberg, AL; Trouva, A; Ujvari, D; Vanky, E, 2023) |
| "Metformin treatment elevates serum MANF levels and alleviates insulin resistance and hyperandrogenism in PCOS women." | 5.56 | Decreased Circulating MANF in Women with PCOS is Elevated by Metformin Therapy and is Inversely Correlated with Insulin Resistance and Hyperandrogenism. ( Deng, W; Jia, Y; Li, Y; Liu, D; Long, M; Wang, C; Wei, J; Yang, G, 2020) |
| "To summarize the effects of metformin treatment on markers of hyperandrogenism in patients diagnosed with polycystic ovary syndrome (PCOS)." | 5.41 | Influence of metformin on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials. ( Cândido, AL; Fontes, AFS; Gomes, KB; Reis, FM; Tosatti, JAG, 2023) |
| "Non-classic congenital adrenal hyperplasia (NC-CAH), one of the most common genetic disorders, is often associated with the clinical features of hyperandrogenism." | 5.40 | The effect of metformin on androgen production in diabetic women with non-classic congenital adrenal hyperplasia. ( Krysiak, R; Okopien, B, 2014) |
| "Metformin treatment, lead to a significant decrease in serum insulin (p = 0." | 5.39 | Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. ( Ferriani, RA; Japur de Sá Rosa-e-Silva, AC; Nascimento, AD; Reis, RM; Silva Lara, LA, 2013) |
| "The aim of this study was to compare the efficacy and safety of adding metformin or spironolactone to rosiglitazone in women with polycystic ovary syndrome (PCOS)." | 5.34 | Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS. ( Bhat, D; Butt, TP; Choh, N; Ganie, MA; Gupta, N; Masoodi, SR; Nisar, S; Rashid, A; Sofi, NY; Sood, M; Wani, IA, 2020) |
| " While metformin has a mild androgen-lowering effect in non-pregnant women with PCOS, its effects on maternal androgen levels in pregnancy are less well understood." | 5.34 | Sustained Maternal Hyperandrogenism During PCOS Pregnancy Reduced by Metformin in Non-obese Women Carrying a Male Fetus. ( Abbott, D; Andræ, F; Odsæter, IH; Salvesen, Ø; Schmedes, AV; Stridsklev, S; Vanky, E, 2020) |
| "Treatment with metformin or rosiglitazone prevents excess adrenal androgen synthesis." | 5.34 | Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. ( Bahtiyar, G; Sacerdote, AS; Weiss, K, 2007) |
| " Indeed, metformin has been involved in repair mitochondrial dysfunction, decrease of oxidative stress, reduction of androgens levels and the enhancing of insulin sensitivity." | 5.22 | Polycystic ovarian syndrome: signs and feedback effects of hyperandrogenism and insulin resistance. ( Barrera, D; Echeverría, O; Escobar, L; Espinoza-Simón, E; González, J; Hernández-Jiménez, JL; Ortíz-Hernández, R; Torres-Ramírez, N, 2022) |
| " Additionally, novel cosmetic techniques like electrolysis, laser and use of topically applied eflornithine to tackle the most distressing feature of facial hirsutism associated with PCOS, non-pharmacological therapy like acupuncture and the role of herbal medicine in PCOS management have also been discussed." | 5.22 | Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. ( Ali, T; Amin, F; Ara, R; Bader, GN; Kareem, O; Malik, A; Mir, SA; Rashid, R, 2022) |
| "Aim of this study was to evaluate the effect of vitamin D supplementation in obese, insulin resistant and vitamin D deficient PCOS women on biochemical and clinical hyperandrogenism and menstrual irregularity in comparison to effect of metformin or combined metformin plus vitamin D therapy." | 5.22 | The effect of alfacalcidiol and metformin on phenotype manifestations in women with polycystic ovary syndrome - a preliminary study. ( Dravecká, I; Figurová, J; Javorský, M; Lazúrová, I; Petríková, J; Vaľková, M, 2016) |
| "Conclusions on the effect of metformin on circulating anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS) are ambiguous." | 5.20 | Impact of metformin on anti-Müllerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial. ( Ingerslev, HJ; Lauszus, FF; Madsen, HN; Trolle, B; Tørring, N, 2015) |
| " It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone." | 5.19 | In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014) |
| "Hyperandrogenaemia in polycystic ovary syndrome (PCOS) represents a composite of raised serum concentrations of testosterone, androstenedione, dehydroepiandrosterone (DHEA) and DHEA sulphate (DHEAS)." | 5.16 | Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. ( Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T; Smith, KA, 2012) |
| "To assess the impact of metformin and of two different oral contraceptives (OCs) containing cyproterone acetate and drospirenone, on serum anti-Müllerian hormone (AMH) levels, in a cohort of women with polycystic ovary syndrome (PCOS) with hyperandrogenism." | 5.15 | The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. ( Decavalas, G; Diamanti-Kandarakis, E; Georgopoulos, NA; Katsikis, I; Panidis, D; Piouka, A; Saltamavros, AD, 2011) |
| "In LBW-PP girls, early metformin therapy was found to prevent or delay the development of hirsutism, androgen excess, oligomenorrhea, and PCOS more effectively than late metformin." | 5.15 | Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Marcos, MV, 2011) |
| "To evaluate the clinical, endocrine and metabolic effects of metformin and N-acetyl-cysteine (NAC) in patients with polycystic ovary syndrome (PCOS)." | 5.15 | Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. ( Muderris, II; Oner, G, 2011) |
| " Both simvastatin and metformin improved menstrual cyclicity and decreased hirsutism, acne, ovarian volume, body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1." | 5.15 | Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. ( Banaszewska, B; Duleba, AJ; Pawelczyk, L; Spaczynski, RZ, 2011) |
| "Only orlistat reduced both IR and its variability significantly, though all three drugs were effective in reducing hyperandrogenism within the 12-week period of the study." | 5.14 | Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. ( Atkin, SL; Cho, LW; Coady, AM; Keevil, BG; Kilpatrick, ES, 2009) |
| "In polycystic ovary syndrome, metformin improves insulin resistance, inflammatory markers, and endothelial function." | 5.14 | Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. ( Hutchison, SK; McGrath, BP; Meyer, C; Moran, LJ; Teede, HJ; Zoungas, S, 2010) |
| "To evaluate the effect of a short-course pretreatment with metformin on hyperandrogenism, insulin resistance, cervical scores, and pregnancy rates in women with clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS)." | 5.14 | Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. ( Ghaffarpasand, F; Kazerooni, M; Kazerooni, T; Kazerooni, Y; Setoodeh, S, 2009) |
| "We studied the effects of the SHBG (TAAAA)(n) and androgen receptor gene [AR] (CAG)(n) allele length on endocrine-metabolic features and body composition (by dual-energy X-ray absorptiometry) before and after 1 year on metformin (850 mg/d) in 70 girls with polycystic ovary syndrome after precocious pubarche; allele lengths were assessed by polymerase chain reaction in both patients and in population control subjects (n = 107)." | 5.14 | Efficacy of metformin therapy in adolescent girls with androgen excess: relation to sex hormone-binding globulin and androgen receptor polymorphisms. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Petry, CJ, 2010) |
| "To compare the effects of insulin sensitization with metformin to weight reduction by rimonabant on biochemical hyperandrogenaemia and insulin resistance in patients with PCOS." | 5.13 | A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. ( Atkin, SL; Cho, LW; Coady, AM; Kilpatrick, ES; Sathyapalan, T, 2008) |
| "Low-dose flutamide-metformin (Flu-Met) with an oral contraceptive is a therapeutic option for women with hyperinsulinaemic hyperandrogenism." | 5.12 | Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-alpha and the neutrophil/lymphocyte ratio. ( de Zegher, F; Ibáñez, L; Valls, C, 2006) |
| " Much better decrease in the level of testosterone and free androgen index was established in group treated with metformin, while the indices of insulin resistance were better influenced in the group treated with rosiglitazone." | 5.12 | Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. ( Mitkov, M; Pehlivanov, B; Terzieva, D, 2006) |
| "One of the treatments for hyperinsulinemic hyperandrogenism in nonobese women is combined androgen receptor blockade (with flutamide; Flu), insulin sensitization (with metformin; Met) plus an estroprogestagen contraceptive." | 5.12 | Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess. ( de Zegher, F; del Rio, L; Enríquez, G; Ibáñez, L; López-Bermejo, A; Valls, C, 2007) |
| "A low-dose combination of flutamide-metformin and ethinylestradiol-drospirenone was recently found to reduce the excess of total and abdominal fat, to diminish the deficit in lean mass, and to attenuate the dysadipocytokinemia of young women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 5.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. ( Cabré, S; De Zegher, F; Ibáñez, L; Valls, C, 2004) |
| "Flutamide (Flu)-metformin (Met) with ethinylestradiol-drospirenone is a combination therapy that reduces the total and abdominal fat excess, diminishes the lean mass deficit, and attenuates the dysadipocytokinemia of young and nonobese women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 5.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. ( de Zegher, F; Ibáñez, L, 2005) |
| "This study was undertaken to evaluate the efficacy of metformin in women with anovulation who do not have evidence for hyperandrogenism and classic polycystic ovary syndrome." | 5.11 | Does metformin induce ovulation in normoandrogenic anovulatory women? ( Carmina, E; Lobo, RA, 2004) |
| " The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment." | 5.11 | Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. ( Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A, 2005) |
| "In adolescents and young women with hyperinsulinaemic hyperandrogenism (n = 118; mean age 16 years, body mass index 22 kg/m(2)), we analysed whether the PCOS-associated rise in leukocyte count is already detectable at young age and, if so, whether such elevation is lowered by metformin, flutamide-metformin, oral contraception (OC), or their combination." | 5.11 | High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception. ( de Zegher, F; Ferrer, A; Ibáñez, L; Jaramillo, AM, 2005) |
| "Most patients with polycystic ovary syndrome (PCOS) have hyperinsulinemia; thus it has been postulated that insulin-lowering drugs, such as metformin, might be a useful long-term choice." | 5.10 | Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. ( De Pergola, G; Lorusso, F; Loverro, G; Mei, L; Nicolardi, V; Selvaggi, L, 2002) |
| "The endocrine-metabolic status of non-obese, young women with polycystic ovary syndrome (PCOS) is normalized more effectively by combined treatment with flutamide and metformin than by either of these drugs in monotherapy." | 5.10 | Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. ( de Zegher, F; Ibáñez, L, 2003) |
| "To evaluate the effects of 12 weeks of metformin therapy on hormonal and clinical indices in polycystic ovary syndrome (PCOS)." | 5.09 | Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. ( Duleba, AJ; Kolodziejczyk, B; Pawelczyk, L; Spaczynski, RZ, 2000) |
| "We measured fasting serum steroid concentrations and the response of serum 17 alpha-hydroxyprogesterone to leuprolide, a gonadotrophin-releasing hormone agonist, and performed oral glucose-tolerance tests before and after oral administration of either metformin (500 mg three times daily) or placebo for four to eight weeks in 24 obese women with the polycystic ovary syndrome." | 5.08 | Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. ( Jakubowicz, DJ; Nestler, JE, 1996) |
| "There is reliable evidence regarding the use of metformin for anthropometric outcomes and COCPs for hyperandrogenism in women with PCOS but not for other interventions." | 4.98 | Pharmacological and surgical treatment of nonreproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews. ( Gadalla, MA; Hiam, DS; Joham, AE; Moran, LJ; Pundir, J; Tay, CT; Teede, HJ; Thangaratinam, S, 2018) |
| ", pioglitazone and metformin) used for the treatment of insulin resistance in PCOS, on androgen production." | 4.93 | Cellular and Animal Studies: Insights into Pathophysiology and Therapy of PCOS. ( Indran, IR; Lee, BH; Yong, EL, 2016) |
| "The use of insulin-sensitising agents, such as metformin, in women with polycystic ovary syndrome (PCOS) who are undergoing ovulation induction or in vitro fertilisation (IVF) cycles has been widely studied." | 4.90 | Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. ( Albuquerque, LE; Andriolo, RB; Costello, MF; Macedo, CR; Tso, LO, 2014) |
| "This article is a review of the literature assessing pregnancy outcomes and the effect of metformin treatment among women with polycystic ovary syndrome (PCOS)." | 4.88 | Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview. ( Awwad, JT; Ghazeeri, GS; Nassar, AH; Younes, Z, 2012) |
| "The use of insulin-sensitising agents, such as metformin, in women with polycystic ovary syndrome (PCOS) who are undergoing ovulation induction or in vitro fertilisation (IVF) cycles has been widely studied." | 4.85 | Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. ( Albuquerque, LE; Andriolo, RB; Costello, MF; Freitas, V; Tso, LO, 2009) |
| "Metformin is a common treatment for women who have insulin resistance manifesting as type 2 diabetes or polycystic ovarian syndrome (PCOS)." | 4.82 | Metformin in obstetric and gynecologic practice: a review. ( Boyle, J; McCarthy, EA; McLachlan, K; Permezel, M; Walker, SP, 2004) |
| " Although no clinical trials over 6 months in duration have assessed the long-term efficacy of metformin use in adolescents, short-term trials have shown promising effects in lowering insulin secretion, improving insulin sensitivity, restoring normal menstrual cycles, and correcting lipid abnormalities." | 4.81 | Polycystic ovary syndrome in adolescents. ( Kent, SC; Legro, RS, 2002) |
| " Weight loss, lifestyle modification and combined hormonal pill and metformin are considered first-line treatment." | 3.96 | Hyperandrogenism, insulin resistance and acanthosis nigricans (HAIR-AN syndrome): an extreme subphenotype of polycystic ovary syndrome. ( Dahiya, R; Kimble, R; O'Brien, B, 2020) |
| "To evaluate the effect of metformin and pioglitazone on leutinizing hormone and follicle stimulating hormone receptor mRNA expression, hyperandrogenism and insulin resistance in high fat diet induced and letrozole induced PCOS in rats." | 3.88 | Insulin Sensitizers Modulate GnRH Receptor Expression in PCOS Rats. ( Patel, R; Shah, G, 2018) |
| "The latest list of reimbursed medicines includes, as a new addition, metformin for the treatment of polycystic ovary syndrome (PCOS), which is extremely important for practicing physicians." | 3.79 | Metformin for polycystic ovary syndrome. ( Milewicz, A, 2013) |
| "To evaluate the ovarian function during early infancy in daughters of women with polycystic ovary syndrome (PCOS) treated with metformin throughout pregnancy (PCOSd+M), as a means to reduce androgen and insulin levels, compared with daughters of nontreated PCOS women (PCOSd-M) and daughters of women who belong to a healthy comparison group (HCd)." | 3.78 | Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular mass of their daughters. ( Crisosto, N; Echiburú, B; Ladrón de Guevara, A; Maliqueo, M; Pérez, V; Preisler, J; Sánchez, F; Sir-Petermann, T, 2012) |
| "We aimed to compare the effects of metformin and metformin-rosuvastatin combination therapies on hyperandrogenism in patients with polycystic ovary syndrome (PCOS)." | 3.78 | Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance. ( Acbay, O; Celik, O, 2012) |
| " We tested the hypothesis that a gene variant in STK11 contributes to variation in insulin sensitivity and metformin efficacy." | 3.76 | A single nucleotide polymorphism in STK11 influences insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Morán, E, 2010) |
| "We evaluated the effect of hyperandrogenism in ovaries with functional and regressing corpora lutea (CL) and the action of metformin in preventing these possible alterations using a mouse model." | 3.75 | Effect of DHEA and metformin on corpus luteum in mice. ( Facorro, GB; Motta, AB; Piehl, L; Rubín de Celis, E; Sander, VA, 2009) |
| " We sought to characterize patients with biochemical hyperandrogenism in respect of tumor versus non-tumor etiologies, explore possible links between non-tumor hyperandrogenism and metabolic syndrome, and ascertain whether metformin therapy can elicit diagnostic reductions in serum testosterone (T)." | 3.74 | The investigation and management of severe hyperandrogenism pre- and postmenopause: non-tumor disease is strongly associated with metabolic syndrome and typically responds to insulin-sensitization with metformin. ( Advani, A; Al-Ozairi, E; Ball, SG; James, RA; Lim, E; Quinton, R; Vaikkakara, S, 2008) |
| "Hyperinsulinemic hyperandrogenism is the core of polycystic ovary syndrome (PCOS), and, accordingly, low-dose flutamide-metformin proved so far to be a most effective approach to normalize the broad spectrum of PCOS anomalies in nonobese adolescents and young women." | 3.73 | Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in nonobese adolescents and women. ( de Zegher, F; Ibáñez, L, 2006) |
| "To observe the efficacy of Chinese herbal formula "Tiangui Fang" (TGF) in hyperandrogenism and hyperinsulinism patients of polycystic ovarian syndrome (PCOS), and compare with western medicine metformin." | 3.70 | [Study on treatment of hyperandrogenism and hyperinsulinism in polycystic ovary syndrome with Chinese herbal formula "tiangui fang"]. ( Hou, J; Wei, M; Yu, J, 2000) |
| "To assess the effects of metformin on tissue insulin sensitivity in obese and hyperandrogenic women." | 3.69 | [Effects of metformin on insulin resistance in obese and hyperandrogenic women]. ( Calvillán, M; Castillo, T; López, G; Muñoz, S; Sir, T, 1997) |
| "Metformin treatment was associated with decreases in testosterone, free androgen index, androstenedione, 17-OH progesterone and estradiol levels." | 2.78 | Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus. ( Asenjo, S; Cassorla, F; Codner, E; Eyzaguirre, FC; Iñíguez, G; López, P; Mujica, V; Torrealba, I, 2013) |
| "Vitamin D deficiency was recompensed in 74% of the PCOS patients who had taken calcium & vitamin D supplementation." | 2.77 | Therapeutic effects of calcium & vitamin D supplementation in women with PCOS. ( Aflatoonian, A; Firouzabadi, Rd; Modarresi, S; MohammadTaheri, S; Sekhavat, L, 2012) |
| "Simvastatin treatment was superior to metformin alone, whereas a combination of simvastatin and metformin was not significantly superior to simvastatin alone." | 2.74 | Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. ( Banaszewska, B; Duleba, AJ; Pawelczyk, L; Spaczynski, RZ, 2009) |
| "Metformin was then given at a dose of 500 mg three times a day for 8 weeks, after which time the pretreatment study was repeated." | 2.71 | Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. ( Dehghan-Kooshkghazi, M; Kazerooni, T, 2003) |
| "Flutamide-metformin treatment (n = 30) was followed within 3 months by marked decreases in hirsutism score and serum androgens, by a more than 50% increase in insulin sensitivity and by a less atherogenic lipid profile (all P < 0." | 2.71 | Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. ( Amin, R; de Zegher, F; Dunger, D; Ferrer, A; Ibáñez, L; Ong, K, 2003) |
| "Metformin treatment was well tolerated." | 2.70 | Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. ( de Zegher, F; Ferrer, A; Ibáñez, L; Marcos, MV; Rodriguez-Hierro, F; Valls, C, 2001) |
| "We hypothesized that dyslipidemia and anovulation in nonobese women with polycystic ovary syndrome are essentially secondary to the concerted effects of hyperandrogenism and insulin resistance." | 2.70 | Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. ( De Zegher, F; Dunger, DB; Ferrer, A; Ibáñez, L; Ong, K; Valls, C, 2002) |
| "Metformin was well tolerated except for one case of flatulence." | 2.69 | Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. ( Bergiele, A; Diamanti-Kandarakis, E; Kouli, C; Tsianateli, T, 1998) |
| "Metformin treatment was well tolerated and was accompanied by a marked drop in hirsutism score, insulin response to oral glucose tolerance test, free androgen index, and baseline testosterone, androstenedione, dehydroepiandrosterone, and dehydroepiandrosterone sulfate levels (all P < 0." | 2.69 | Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. ( de Zegher, F; Ibáñez, L; Marcos, MV; Potau, N; Valls, C, 2000) |
| "The link between NAFLD/NASH and PCOS is not just a coincidence." | 2.53 | Hepatic manifestations of women with polycystic ovary syndrome. ( Chen, MJ; Ho, HN, 2016) |
| "Obesity is now a major international health concern." | 2.52 | Obesity and polycystic ovary syndrome. ( Boyle, J; De Courten, B; Joham, A; Naderpoor, N; Shorakae, S; Teede, HJ, 2015) |
| "Polycystic ovary syndrome is recognized as the most common hormonal and metabolic disorder likely to affect women." | 2.52 | [Evidence-based therapy of polycystic ovarian syndrome]. ( Csenteri, OK; Gődény, S, 2015) |
| "Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2 diabetes mellitus." | 2.45 | Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2009) |
| "Metformin has been shown to reduce ovarian production, enhance ovulatory cycles and in some cases increase fertility." | 2.42 | [Insulin resistance and polycystic ovary syndrome]. ( Basille, C; Bernard, L; Chabbert-Buffet, N; Christin-Maître, S, 2003) |
| "Polycystic ovary syndrome is a frequent endocrine disorder often associated with insulin resistance and hyperinsulinaemia which may play a role in hyperandrogenism and anovulation." | 2.42 | [Should infertile women with polycystic ovarian syndrome be treated with metformine?]. ( Basille, C; Bry-Gauillard, H; Cédrin-Durnerin, I; Galey, J; Hugues, JN; Massin, N; Théron-Gérard, L, 2003) |
| "While the treatment of hyperandrogenism makes use of different drugs already studied, the debate about the use of insulin sensitizing drugs is still open." | 2.42 | Which treatment options should be used in adolescents with polycystic ovary syndrome? ( Barini, A; Di Sebastiano, F; Fulghesu, AM; Lanzone, A; Rossodivita, A; Sagnella, F; Villa, P, 2004) |
| "Women with severe insulin resistance are a unique subset of polycystic ovary syndrome." | 2.41 | Induction of ovulation in infertile women with hyperandrogenism and insulin resistance. ( Barbieri, RL, 2000) |
| "Medical treatments for hirsutism often need to be combined with physical therapies for optimal management." | 1.91 | An evaluation of the available pharmacotherapy for the treatment of hirsutism. ( Asfour, L; Kazmi, A; Sinclair, R, 2023) |
| "Metformin treatment elevates serum MANF levels and alleviates insulin resistance and hyperandrogenism in PCOS women." | 1.56 | Decreased Circulating MANF in Women with PCOS is Elevated by Metformin Therapy and is Inversely Correlated with Insulin Resistance and Hyperandrogenism. ( Deng, W; Jia, Y; Li, Y; Liu, D; Long, M; Wang, C; Wei, J; Yang, G, 2020) |
| "Polycystic ovary syndrome is the most common endocrinopathy among reproductive-aged women in the United States, affecting approximately 7% of female patients." | 1.43 | Diagnosis and Treatment of Polycystic Ovary Syndrome. ( Mortada, R; Porter, S; Williams, T, 2016) |
| "Metformin was added according to its indication." | 1.42 | Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes. ( Jin, J; Mueck, AO; Ruan, X; Wu, H, 2015) |
| "Non-classic congenital adrenal hyperplasia (NC-CAH), one of the most common genetic disorders, is often associated with the clinical features of hyperandrogenism." | 1.40 | The effect of metformin on androgen production in diabetic women with non-classic congenital adrenal hyperplasia. ( Krysiak, R; Okopien, B, 2014) |
| "Metformin treatment, lead to a significant decrease in serum insulin (p = 0." | 1.39 | Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. ( Ferriani, RA; Japur de Sá Rosa-e-Silva, AC; Nascimento, AD; Reis, RM; Silva Lara, LA, 2013) |
| "Treatment with metformin or rosiglitazone prevents excess adrenal androgen synthesis." | 1.34 | Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. ( Bahtiyar, G; Sacerdote, AS; Weiss, K, 2007) |
| "When metformin was administered together with DHEA, the ovarian GSH content, NOS activity and PGE production did not differ when compared with controls." | 1.33 | The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice. ( Di Girolamo, G; Elia, E; Gonzalez, C; Luchetti, CG; Motta, AB; Sander, V; Solano, ME, 2006) |
| "Metformin treatment did not modify the percentage of CD4(+) and CD8(+) T cells from both axillar and retroperitoneal lymph nodes but prevented the increase of serum tumour necrosis factor +/- produced in DHEA-treated mice." | 1.33 | Metformin prevents embryonic resorption induced by hyperandrogenisation with dehydroepiandrosterone in mice. ( Di Girolamo, G; Elia, E; Gonzalez, C; Luchetti, CG; Motta, AB; Sander, V; Solano, ME, 2006) |
"Metformin treatment was accompanied by a drop in fasting insulin and serum androgens and by a less atherogenic lipid profile (all P | 1.31 | Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. ( De Zegher, F; Ferrer, A; Ibáñez, L; Marcos, MV; Potau, N; Rodriguez-Hierro, F, 2002) | |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (3.45) | 18.2507 |
| 2000's | 53 (36.55) | 29.6817 |
| 2010's | 66 (45.52) | 24.3611 |
| 2020's | 21 (14.48) | 2.80 |
| Authors | Studies |
|---|---|
| Hernández-Jiménez, JL | 1 |
| Barrera, D | 1 |
| Espinoza-Simón, E | 1 |
| González, J | 1 |
| Ortíz-Hernández, R | 1 |
| Escobar, L | 1 |
| Echeverría, O | 1 |
| Torres-Ramírez, N | 1 |
| Garzia, E | 1 |
| Galiano, V | 1 |
| Marfia, G | 1 |
| Navone, S | 1 |
| Grossi, E | 1 |
| Marconi, AM | 1 |
| Rashid, R | 1 |
| Mir, SA | 1 |
| Kareem, O | 1 |
| Ali, T | 1 |
| Ara, R | 1 |
| Malik, A | 1 |
| Amin, F | 1 |
| Bader, GN | 1 |
| Abdalla, MA | 1 |
| Shah, N | 1 |
| Deshmukh, H | 1 |
| Sahebkar, A | 1 |
| Östlundh, L | 1 |
| Al-Rifai, RH | 1 |
| Atkin, SL | 5 |
| Sathyapalan, T | 4 |
| Froment, P | 1 |
| Plotton, I | 1 |
| Giulivi, C | 1 |
| Fabre, S | 1 |
| Khoueiry, R | 1 |
| Mourad, NI | 1 |
| Horman, S | 1 |
| Ramé, C | 1 |
| Rouillon, C | 1 |
| Grandhaye, J | 1 |
| Bigot, Y | 1 |
| Chevaleyre, C | 1 |
| Le Guevel, R | 1 |
| Mallegol, P | 1 |
| Andriantsitohaina, R | 1 |
| Guerif, F | 1 |
| Tamburini, J | 1 |
| Viollet, B | 1 |
| Foretz, M | 1 |
| Dupont, J | 1 |
| Manique, MES | 1 |
| Ferreira, AMAP | 1 |
| Smirnov, VV | 1 |
| Beeraka, NM | 1 |
| Butko, DY | 1 |
| Nikolenko, VN | 1 |
| Bondarev, SA | 1 |
| Achkasov, EE | 1 |
| Sinelnikov, MY | 1 |
| Vikram, PRH | 1 |
| Joham, AE | 2 |
| Norman, RJ | 2 |
| Stener-Victorin, E | 1 |
| Legro, RS | 3 |
| Franks, S | 2 |
| Moran, LJ | 3 |
| Boyle, J | 3 |
| Teede, HJ | 5 |
| Hancke, K | 1 |
| Fontes, AFS | 1 |
| Reis, FM | 1 |
| Cândido, AL | 1 |
| Gomes, KB | 1 |
| Tosatti, JAG | 1 |
| Asfour, L | 1 |
| Kazmi, A | 1 |
| Sinclair, R | 1 |
| DiVall, SA | 1 |
| Ujvari, D | 1 |
| Trouva, A | 1 |
| Hirschberg, AL | 1 |
| Vanky, E | 2 |
| Carvalho, MJ | 1 |
| Subtil, S | 1 |
| Rodrigues, Â | 1 |
| Oliveira, J | 1 |
| Figueiredo-Dias, M | 1 |
| Ganie, MA | 1 |
| Rashid, A | 1 |
| Sood, M | 1 |
| Sofi, NY | 1 |
| Wani, IA | 1 |
| Nisar, S | 1 |
| Butt, TP | 1 |
| Gupta, N | 1 |
| Bhat, D | 1 |
| Choh, N | 1 |
| Masoodi, SR | 1 |
| Zeng, X | 1 |
| Xie, YJ | 1 |
| Liu, YT | 1 |
| Long, SL | 1 |
| Mo, ZC | 1 |
| Vatopoulou, A | 1 |
| Tziomalos, K | 1 |
| Wei, J | 1 |
| Wang, C | 2 |
| Yang, G | 1 |
| Jia, Y | 1 |
| Li, Y | 1 |
| Deng, W | 1 |
| Long, M | 1 |
| Liu, D | 1 |
| O'Brien, B | 1 |
| Dahiya, R | 1 |
| Kimble, R | 1 |
| Nejabati, HR | 1 |
| Samadi, N | 1 |
| Shahnazi, V | 1 |
| Mihanfar, A | 1 |
| Fattahi, A | 1 |
| Latifi, Z | 1 |
| Bahrami-Asl, Z | 1 |
| Roshangar, L | 1 |
| Nouri, M | 1 |
| Andræ, F | 1 |
| Abbott, D | 1 |
| Stridsklev, S | 1 |
| Schmedes, AV | 1 |
| Odsæter, IH | 1 |
| Salvesen, Ø | 1 |
| Bjekić-Macut, J | 1 |
| Vukašin, T | 1 |
| Velija-Ašimi, Z | 1 |
| Bureković, A | 1 |
| Zdravković, M | 1 |
| Andrić, Z | 1 |
| Branković, M | 1 |
| Crevar-Marinović, S | 1 |
| Madić, T | 1 |
| Stanojlović, O | 1 |
| Milutinović, DV | 1 |
| Livadas, S | 1 |
| Mastorakos, G | 1 |
| Zhang, Y | 1 |
| Hu, M | 1 |
| Meng, F | 1 |
| Sun, X | 1 |
| Xu, H | 1 |
| Zhang, J | 1 |
| Cui, P | 1 |
| Morina, N | 1 |
| Li, X | 1 |
| Li, W | 1 |
| Wu, XK | 1 |
| Brännström, M | 1 |
| Shao, R | 1 |
| Billig, H | 1 |
| Morgante, G | 1 |
| Massaro, MG | 1 |
| Di Sabatino, A | 1 |
| Cappelli, V | 1 |
| De Leo, V | 1 |
| Lundgren, JA | 1 |
| Kim, SH | 1 |
| Burt Solorzano, CM | 1 |
| McCartney, CR | 1 |
| Marshall, JC | 1 |
| Dos Santos, IK | 1 |
| de Lima Nunes, R | 1 |
| Soares, GM | 1 |
| de Oliveira Maranhão, TM | 1 |
| Dantas, PMS | 1 |
| Pal Singh Kochar, I | 1 |
| Ramachandran, S | 1 |
| Sethi, A | 1 |
| Tay, CT | 1 |
| Hiam, DS | 1 |
| Gadalla, MA | 1 |
| Pundir, J | 1 |
| Thangaratinam, S | 1 |
| Patel, R | 1 |
| Shah, G | 1 |
| Tang, L | 1 |
| Ye, J | 1 |
| Shi, Y | 1 |
| Zhu, X | 1 |
| Abruzzese, GA | 1 |
| Heber, MF | 1 |
| Ferrer, MJ | 1 |
| Ferreira, SR | 1 |
| Silva, AF | 1 |
| Motta, AB | 7 |
| Hafez, M | 1 |
| Musa, N | 1 |
| Elbehairy, S | 1 |
| Atty, SA | 1 |
| Elbarbary, M | 1 |
| Amin, M | 1 |
| Mazza, A | 1 |
| Fruci, B | 1 |
| Guzzi, P | 1 |
| D'Orrico, B | 1 |
| Malaguarnera, R | 1 |
| Veltri, P | 1 |
| Fava, A | 1 |
| Belfiore, A | 1 |
| Pasquali, R | 2 |
| Gambineri, A | 2 |
| Milewicz, A | 1 |
| Codner, E | 1 |
| Iñíguez, G | 1 |
| López, P | 1 |
| Mujica, V | 1 |
| Eyzaguirre, FC | 1 |
| Asenjo, S | 1 |
| Torrealba, I | 1 |
| Cassorla, F | 1 |
| Barthelmess, EK | 1 |
| Naz, RK | 1 |
| Ferreira, GD | 1 |
| Germeyer, A | 1 |
| de Barros Machado, A | 1 |
| do Nascimento, TL | 1 |
| Strowitzki, T | 1 |
| Brum, IS | 1 |
| von Eye Corleta, H | 1 |
| Capp, E | 1 |
| Ibáñez, L | 27 |
| Ong, KK | 2 |
| López-Bermejo, A | 11 |
| Dunger, DB | 3 |
| de Zegher, F | 25 |
| Conway, G | 1 |
| Dewailly, D | 2 |
| Diamanti-Kandarakis, E | 3 |
| Escobar-Morreale, HF | 2 |
| Kelestimur, F | 1 |
| Macut, D | 1 |
| Micic, D | 1 |
| Pfeifer, M | 1 |
| Pignatelli, D | 1 |
| Pugeat, M | 1 |
| Yildiz, B | 1 |
| Krysiak, R | 1 |
| Okopien, B | 1 |
| Kurzthaler, D | 1 |
| Hadziomerovic-Pekic, D | 1 |
| Wildt, L | 1 |
| Seeber, BE | 1 |
| Tso, LO | 2 |
| Costello, MF | 2 |
| Albuquerque, LE | 2 |
| Andriolo, RB | 2 |
| Macedo, CR | 1 |
| Naderpoor, N | 1 |
| Shorakae, S | 1 |
| Joham, A | 1 |
| De Courten, B | 1 |
| Messinis, IE | 1 |
| Messini, CI | 1 |
| Anifandis, G | 1 |
| Dafopoulos, K | 1 |
| Madsen, HN | 1 |
| Lauszus, FF | 1 |
| Trolle, B | 1 |
| Ingerslev, HJ | 1 |
| Tørring, N | 1 |
| Wu, H | 1 |
| Ruan, X | 1 |
| Jin, J | 1 |
| Mueck, AO | 1 |
| Spritzer, PM | 1 |
| Hurliman, A | 1 |
| Keller Brown, J | 1 |
| Maille, N | 1 |
| Mandala, M | 1 |
| Casson, P | 1 |
| Osol, G | 1 |
| Vrbíková, J | 1 |
| Goodman, NF | 1 |
| Cobin, RH | 1 |
| Futterweit, W | 1 |
| Glueck, JS | 1 |
| Carmina, E | 2 |
| Díaz, M | 10 |
| Gallego-Escuredo, JM | 1 |
| Villarroya, F | 1 |
| Gődény, S | 1 |
| Csenteri, OK | 1 |
| Chen, MJ | 1 |
| Ho, HN | 1 |
| Indran, IR | 1 |
| Lee, BH | 1 |
| Yong, EL | 1 |
| Williams, T | 1 |
| Mortada, R | 1 |
| Porter, S | 1 |
| Dravecká, I | 1 |
| Figurová, J | 1 |
| Javorský, M | 1 |
| Petríková, J | 1 |
| Vaľková, M | 1 |
| Lazúrová, I | 1 |
| Javed, Z | 1 |
| Kilpatrick, ES | 4 |
| Coady, AM | 4 |
| Kępczyńska-Nyk, A | 1 |
| Muszel, M | 1 |
| Radziszewski, M | 1 |
| Wocial, K | 1 |
| Cho, LW | 2 |
| Keevil, BG | 1 |
| Wu, J | 1 |
| Zhu, Y | 1 |
| Jiang, Y | 1 |
| Cao, Y | 1 |
| Meyer, C | 2 |
| Hutchison, SK | 1 |
| Zoungas, S | 1 |
| McGrath, BP | 1 |
| Palomba, S | 1 |
| Falbo, A | 1 |
| Zullo, F | 1 |
| Orio, F | 1 |
| Freitas, V | 1 |
| Sander, VA | 1 |
| Facorro, GB | 1 |
| Piehl, L | 1 |
| Rubín de Celis, E | 1 |
| Kazerooni, T | 2 |
| Ghaffarpasand, F | 1 |
| Kazerooni, Y | 1 |
| Kazerooni, M | 1 |
| Setoodeh, S | 1 |
| Banaszewska, B | 2 |
| Pawelczyk, L | 3 |
| Spaczynski, RZ | 3 |
| Duleba, AJ | 3 |
| Duranteau, L | 1 |
| Lefevre, P | 1 |
| Jeandidier, N | 1 |
| Simon, T | 1 |
| Christin-Maitre, S | 2 |
| Artini, PG | 1 |
| Di Berardino, OM | 1 |
| Simi, G | 1 |
| Papini, F | 1 |
| Ruggiero, M | 1 |
| Monteleone, P | 1 |
| Cela, V | 1 |
| Langmár, Z | 1 |
| Morán, E | 1 |
| Genazzani, AD | 2 |
| Ricchieri, F | 2 |
| Lanzoni, C | 2 |
| Petry, CJ | 1 |
| Panidis, D | 1 |
| Georgopoulos, NA | 1 |
| Piouka, A | 1 |
| Katsikis, I | 1 |
| Saltamavros, AD | 1 |
| Decavalas, G | 1 |
| Elia, EM | 1 |
| Pustovrh, C | 1 |
| Amalfi, S | 1 |
| Devoto, L | 1 |
| Sánchez-Infantes, D | 2 |
| Bassols, J | 1 |
| Lázaro, I | 1 |
| Cabré, A | 1 |
| Masana, L | 1 |
| Marcos, MV | 5 |
| Boguszewski, MC | 1 |
| Mericq, V | 1 |
| Bergada, I | 1 |
| Damiani, D | 1 |
| Belgorosky, A | 1 |
| Gunczler, P | 1 |
| Ortiz, T | 1 |
| Llano, M | 1 |
| Domené, HM | 1 |
| Calzada-León, R | 1 |
| Blanco, A | 1 |
| Barrientos, M | 1 |
| Procel, P | 1 |
| Lanes, R | 1 |
| Jaramillo, O | 1 |
| Oner, G | 1 |
| Muderris, II | 1 |
| Sebastiani, G | 1 |
| Salvador, C | 2 |
| Smith, KA | 1 |
| Raval, AD | 1 |
| Hunter, T | 1 |
| Stuckey, B | 1 |
| Hart, RJ | 1 |
| Crisosto, N | 1 |
| Echiburú, B | 1 |
| Maliqueo, M | 1 |
| Pérez, V | 1 |
| Ladrón de Guevara, A | 1 |
| Preisler, J | 1 |
| Sánchez, F | 1 |
| Sir-Petermann, T | 1 |
| Ghazeeri, GS | 1 |
| Nassar, AH | 1 |
| Younes, Z | 1 |
| Awwad, JT | 1 |
| Firouzabadi, Rd | 1 |
| Aflatoonian, A | 1 |
| Modarresi, S | 1 |
| Sekhavat, L | 1 |
| MohammadTaheri, S | 1 |
| Celik, O | 1 |
| Acbay, O | 1 |
| Chacón, MR | 1 |
| Maymó-Masip, E | 1 |
| Vendrell, J | 1 |
| Veilleux-Lemieux, M | 1 |
| DiVasta, AD | 1 |
| Nascimento, AD | 1 |
| Silva Lara, LA | 1 |
| Japur de Sá Rosa-e-Silva, AC | 1 |
| Ferriani, RA | 1 |
| Reis, RM | 1 |
| Loverro, G | 1 |
| Lorusso, F | 1 |
| De Pergola, G | 1 |
| Nicolardi, V | 1 |
| Mei, L | 1 |
| Selvaggi, L | 1 |
| Potau, N | 3 |
| Ferrer, A | 5 |
| Rodriguez-Hierro, F | 2 |
| Bernard, L | 1 |
| Basille, C | 2 |
| Chabbert-Buffet, N | 1 |
| Dehghan-Kooshkghazi, M | 1 |
| Massin, N | 1 |
| Galey, J | 1 |
| Théron-Gérard, L | 1 |
| Bry-Gauillard, H | 1 |
| Cédrin-Durnerin, I | 1 |
| Hugues, JN | 1 |
| Ong, K | 2 |
| Amin, R | 1 |
| Dunger, D | 1 |
| Frank-Raue, K | 1 |
| Schulze, E | 1 |
| McCarthy, EA | 1 |
| Walker, SP | 1 |
| McLachlan, K | 1 |
| Permezel, M | 1 |
| Heymann, WR | 1 |
| Villa, P | 1 |
| Di Sebastiano, F | 1 |
| Rossodivita, A | 1 |
| Sagnella, F | 1 |
| Barini, A | 1 |
| Fulghesu, AM | 1 |
| Lanzone, A | 1 |
| Gomel, V | 1 |
| Yarali, H | 1 |
| Valls, C | 7 |
| Cabré, S | 1 |
| Lobo, RA | 1 |
| Ortega-González, C | 1 |
| Luna, S | 1 |
| Hernández, L | 1 |
| Crespo, G | 1 |
| Aguayo, P | 1 |
| Arteaga-Troncoso, G | 1 |
| Parra, A | 1 |
| Jaramillo, AM | 1 |
| Mitkov, M | 1 |
| Pehlivanov, B | 1 |
| Terzieva, D | 1 |
| Elia, E | 2 |
| Sander, V | 2 |
| Luchetti, CG | 2 |
| Solano, ME | 2 |
| Di Girolamo, G | 2 |
| Gonzalez, C | 2 |
| del Rio, L | 1 |
| Enríquez, G | 2 |
| Dronavalli, S | 1 |
| Ehrmann, DA | 1 |
| Baraldi, E | 1 |
| Casarosa, E | 1 |
| Jasonni, VM | 1 |
| Martínez-Bermejo, E | 1 |
| Luque-Ramírez, M | 1 |
| Bahtiyar, G | 1 |
| Weiss, K | 1 |
| Sacerdote, AS | 1 |
| Vaikkakara, S | 1 |
| Al-Ozairi, E | 1 |
| Lim, E | 1 |
| Advani, A | 1 |
| Ball, SG | 1 |
| James, RA | 1 |
| Quinton, R | 1 |
| Nader, S | 1 |
| Dunaif, A | 1 |
| Nestler, JE | 1 |
| Jakubowicz, DJ | 1 |
| Utiger, RD | 1 |
| Kouli, C | 1 |
| Tsianateli, T | 1 |
| Bergiele, A | 1 |
| Sir, T | 1 |
| Castillo, T | 1 |
| Muñoz, S | 1 |
| López, G | 1 |
| Calvillán, M | 1 |
| Sarlis, NJ | 1 |
| Weil, SJ | 1 |
| Nelson, LM | 1 |
| Rique, S | 1 |
| Carrascosa, A | 1 |
| Kolodziejczyk, B | 1 |
| Taylor, AE | 1 |
| Barbieri, RL | 1 |
| Nardo, LG | 1 |
| Rai, R | 1 |
| Hou, J | 1 |
| Yu, J | 1 |
| Wei, M | 1 |
| Kent, SC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and Infertility[NCT05952882] | Phase 3 | 188 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome (PCOS)[NCT00159536] | Phase 3 | 257 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenemic Adolescent Girls (JCM025)[NCT01427595] | 25 participants (Actual) | Interventional | 2009-02-18 | Completed | |||
| Metformin Versus Metfotmin Plus Low-dose Spironolactone in the Treatment of Overweight/Obese Patients With Polycystic Ovary Syndrome: a Randomized Study[NCT01526616] | 56 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients[NCT03151005] | Phase 4 | 70 participants (Actual) | Interventional | 2017-07-01 | Completed | ||
| Randomized, Cross-over Trial With Metformin in Women With Polycystic Ovary Syndrome[NCT02280057] | Phase 4 | 56 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment[NCT05298657] | 200 participants (Anticipated) | Observational [Patient Registry] | 2022-09-01 | Not yet recruiting | |||
| Effect of Myoinositol on Serum Asprosin Levels in PCOS Patients[NCT05951309] | 30 participants (Actual) | Interventional | 2021-09-01 | Completed | |||
| Effect of Simvastatin and Metformin on Clinical, Endocrine, Metabolic and Endothelial Function of Women With Polycystic Ovary Syndrome: Prospective Randomised Trial[NCT00396513] | 0 participants | Interventional | 2005-09-30 | Recruiting | |||
| A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes[NCT01881828] | Phase 3 | 164 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Effects of Metformin and Combination of Metformin and Pioglitazone on Plasma Interleukin-6 and Interleukin-8 Levels in Polycystic Ovarian Syndrome[NCT03117517] | Early Phase 1 | 106 participants (Actual) | Interventional | 2017-03-20 | Completed | ||
| Effect of Metformin and Combination of Olive Oil Plus Nutritional Supplements on Inflammatory Markers IL-6 and IL-8 in PCOS.[NCT05952349] | Phase 2 | 88 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| PCOS, Sleep Apnea and Metabolic Risk in Women[NCT00696111] | 80 participants (Anticipated) | Interventional | 2007-12-31 | Active, not recruiting | |||
| The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial[NCT02491333] | Phase 3 | 342 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| The Effect of Semaglutide Compared to Metformin in Obese Women With Polycystic Ovary Syndrome (PCOS): a Randomised Controlled Study (Semaglutide-PCOS Trial).[NCT05646199] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The progesterone (P4) sensitivity index is defined as the percent change in 11-hour LH pulse frequency before and after P4 and estradiol administration for 7 days, divided by the day 7 mean serum P4 concentration. We compared the P4 sensitivity index after metformin administration to the baseline P4 sensitivity index, using Wilcoxon signed-rank test. (NCT01427595)
Timeframe: 12 weeks following start of metformin treatment
| Intervention | % change in LH pulses/day 7 P4 level (Mean) | |
|---|---|---|
| Before Metformin | After Metformin | |
| Metformin, Progesterone , Estrace | -4.12 | -4.29 |
Systolic blood pressure was measured in mmHg. (NCT03151005)
Timeframe: 12 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 122.83 |
| Metformin-Oral Contraceptive(OC) | 122.40 |
Alanine transaminase was measured in IU/L. (NCT03151005)
Timeframe: 12 weeks
| Intervention | IU/L (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 39.09 |
| Metformin-Oral Contraceptive(OC) | 36.73 |
Changes in testosterone levels were measured (NCT03151005)
Timeframe: 12 weeks
| Intervention | nmol/L (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 1.82 |
| Metformin-Oral Contraceptive(OC) | 2.14 |
Concentration of LH was measured in mIU/ml. (NCT03151005)
Timeframe: 12 weeks
| Intervention | mIU/ml (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 5.52 |
| Metformin-Oral Contraceptive(OC) | 5.33 |
Weight and height will be combined to report BMI in kg/m^2. (NCT03151005)
Timeframe: 12 weeks
| Intervention | kg/m^2 (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 26.26 |
| Metformin-Oral Contraceptive(OC) | 27.12 |
Change in percent body fat (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of change (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentile (Mean) |
|---|---|
| Metformin | -1 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | insulin per kg (Mean) |
|---|---|
| Metformin | -0.1 |
| Oral Placebo | -0.0 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | centimeters (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Change in Systolic | Change in Diastolic | |
| Metformin | 0 | 0 |
| Oral Placebo | -0 | 0 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage (Mean) | |
|---|---|---|
| HbA1c | Change from Baseline to 26 Weeks | |
| Metformin | 9.0 | 0.2 |
| Oral Placebo | 8.9 | 0.2 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| HbA1c Decrease ≥0.5% | HbA1c Increase ≥0.5% | HbA1c <7.5% | |
| Metformin | 19 | 44 | 3 |
| Oral Placebo | 18 | 35 | 4 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| Change in LDL | Change in VLDL | Change in HDL | Change in Triglycerides | Change in Total Cholesterol | |
| Metformin | -6 | -0 | -0 | 4 | -5 |
| Oral Placebo | 2 | 1 | -1 | 6 | 3 |
IL-6 and IL-8 levels by ELISA method using commercially available kits. (NCT03117517)
Timeframe: Baseline and after 3 Months
| Intervention | pg/ml (Geometric Mean) | |||
|---|---|---|---|---|
| IL-6 levels at baseline | IL-6 levels after 3 months of treatment | IL-8 Llevels at baseline | IL-8 Llevels after treatment | |
| Metformin | 14.60 | 12.65 | 61.92 | 32.70 |
| Metformin, Pioglitazone | 14.12 | 11.12 | 41.86 | 22.00 |
Serum level of LH was measure at baseline and after 3 months of treatment (NCT03117517)
Timeframe: Baseine and after 3 Months
| Intervention | mIU/ml (Geometric Mean) | |
|---|---|---|
| LH level at baseline | LH level after treatment | |
| Metformin | 5.79 | 4.92 |
| Metformin, Pioglitazone | 6.625 | 5.16 |
Insulin resistance was measure by calculating HOMA-IR from the data of insulin and sugar levels. (NCT03117517)
Timeframe: Baseline and after 3 months
| Intervention | unitless (Mean) | |
|---|---|---|
| HOMA-IR at baseline | HOMA-IR after treatment | |
| Metformin | 7.19 | 3.97 |
| Metformin, Pioglitazone | 6.22 | 3.84 |
42 reviews available for metformin and Hyperandrogenism
| Article | Year |
|---|---|
Polycystic ovarian syndrome: signs and feedback effects of hyperandrogenism and insulin resistance.
Topics: Androgens; Electron Transport; Feedback, Physiological; Female; Humans; Hyperandrogenism; Hyperinsul | 2022 |
Polycystic ovarian syndrome-current pharmacotherapy and clinical implications.
Topics: Acupuncture; Anovulation; Eflornithine; Female; Herbal Medicine; Hirsutism; Humans; Hydroxymethylglu | 2022 |
Impact of pharmacological interventions on biochemical hyperandrogenemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials.
Topics: Androgens; Dexamethasone; Female; Flutamide; Humans; Hyperandrogenism; Metformin; Polycystic Ovary S | 2023 |
Updates on Molecular Targets and Epigenetic-Based Therapies for PCOS.
Topics: Female; Humans; Hyperandrogenism; Infertility; Insulin Resistance; Metformin; Polycystic Ovary Syndr | 2023 |
Polycystic ovary syndrome.
Topics: Female; Humans; Hyperandrogenism; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome | 2022 |
Influence of metformin on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.
Topics: Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Randomi | 2023 |
Practical considerations for diagnosis and treatment of polycystic ovary syndrome in adolescence - distilling guidelines into clinical practice.
Topics: Adolescent; Adult; Female; Humans; Hyperandrogenism; Life Style; Menstruation Disturbances; Metformi | 2023 |
Controversial association between polycystic ovary syndrome and breast cancer.
Topics: Androgens; Anovulation; Aromatase Inhibitors; Breast Neoplasms; Clomiphene; Contraceptives, Oral, Co | 2019 |
Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
Topics: Androgens; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obe | 2020 |
Management of obesity in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Female; Humans; Hyperandrogenism; Insulin Resistance; Life Style; Metformin; Pediatric O | 2020 |
Polycystic Ovary Syndrome: A Contemporary Clinical Approach.
Topics: Female; Humans; Hyperandrogenism; Insulin Resistance; Metabolic Syndrome; Metformin; Polycystic Ovar | 2021 |
Therapeutic approach for metabolic disorders and infertility in women with PCOS.
Topics: Androgen Antagonists; Anovulation; Clomiphene; Contraceptives, Oral, Hormonal; Female; Gonadotropins | 2018 |
Pharmacological and surgical treatment of nonreproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews.
Topics: Contraceptives, Oral, Combined; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Metformin; Po | 2018 |
Insulin sensitizers in polycystic ovary syndrome.
Topics: Animals; Clomiphene; Diabetes Mellitus, Type 2; Female; Humans; Hyperandrogenism; Hyperinsulinism; I | 2013 |
Polycystic ovary syndrome: current status and future perspective.
Topics: Androgens; Disease Management; Female; Humans; Hyperandrogenism; Infertility, Female; Insulin Resist | 2014 |
Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.
Topics: Female; Fertilization in Vitro; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Live | 2014 |
Obesity and polycystic ovary syndrome.
Topics: Adipokines; Bariatric Surgery; Combined Modality Therapy; Comorbidity; Diet, Reducing; Exercise Ther | 2015 |
Adolescence and polycystic ovary syndrome: current concepts on diagnosis and treatment.
Topics: Adolescent; Androgen Antagonists; Contraceptives, Oral; Female; Hirsutism; Hormones; Humans; Hyperan | 2015 |
[Polycystic ovary syndrome].
Topics: Androgen Antagonists; Anovulation; Combined Modality Therapy; Contraceptives, Oral, Hormonal; Diabet | 2015 |
[Evidence-based therapy of polycystic ovarian syndrome].
Topics: Amenorrhea; Androgen Antagonists; Anovulation; Anti-Obesity Agents; Chorionic Gonadotropin; Contrace | 2015 |
Hepatic manifestations of women with polycystic ovary syndrome.
Topics: Alanine Transaminase; Androgen Antagonists; Aspartate Aminotransferases; Contraceptives, Oral, Hormo | 2016 |
Cellular and Animal Studies: Insights into Pathophysiology and Therapy of PCOS.
Topics: Androgens; Animals; Death Domain Receptor Signaling Adaptor Proteins; Decanoic Acids; Disease Models | 2016 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.
Topics: Female; Fertilization in Vitro; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Live | 2009 |
Should physicians prescribe metformin to women with polycystic ovary syndrome PCOS?
Topics: Adult; Body Mass Index; Clomiphene; Diabetes Mellitus; Diabetes, Gestational; Female; Fertility Agen | 2010 |
Best methods for identification and treatment of PCOS.
Topics: Androgens; Aromatase Inhibitors; Clomiphene; Contraceptives, Oral, Hormonal; Diagnosis, Differential | 2010 |
Dehydroepiandrosterone to induce murine models for the study of polycystic ovary syndrome.
Topics: Androgens; Animals; Dehydroepiandrosterone; Disease Models, Animal; Embryo Loss; Female; Humans; Hyp | 2010 |
Use of metformin in the treatment of polycystic ovary syndrome.
Topics: Adaptation, Psychological; Body Mass Index; Endocrine System; Female; Humans; Hyperandrogenism; Hypo | 2010 |
Statins for women with polycystic ovary syndrome not actively trying to conceive.
Topics: Adult; Atorvastatin; Female; Heptanoic Acids; Hirsutism; Humans; Hydroxymethylglutaryl-CoA Reductase | 2011 |
Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview.
Topics: Abortion, Spontaneous; Diabetes, Gestational; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hyp | 2012 |
[Insulin resistance and polycystic ovary syndrome].
Topics: Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metf | 2003 |
[Should infertile women with polycystic ovarian syndrome be treated with metformine?].
Topics: Clomiphene; Drug Synergism; Estrogen Antagonists; Female; Fertility Agents, Female; Humans; Hyperand | 2003 |
Metformin in obstetric and gynecologic practice: a review.
Topics: Abortion, Spontaneous; Anovulation; Diabetes Mellitus, Type 2; Female; Gastrointestinal Tract; Human | 2004 |
Which treatment options should be used in adolescents with polycystic ovary syndrome?
Topics: Adolescent; Adolescent Health Services; Adult; Androgen Antagonists; Estrogens; Female; Flutamide; H | 2004 |
Insulin-sensitisers in the treatment of polycystic ovary syndrome.
Topics: Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Drug Approval; Exercise; Fema | 2005 |
Obesity and the polycystic ovary syndrome.
Topics: Adrenal Glands; Adult; Androgens; Cardiovascular Diseases; Contraceptives, Oral, Hormonal; Diet; Fem | 2007 |
Ovulation induction in polycystic ovary syndrome.
Topics: Adult; Anovulation; Aromatase Inhibitors; Body Mass Index; Clomiphene; Diathermy; Female; Fertility | 2008 |
Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Hyperandrogenism; Infertility; Insulin Resista | 2008 |
Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Hyperandrogenism; Infertility; Insulin Resista | 2008 |
Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Hyperandrogenism; Infertility; Insulin Resista | 2008 |
Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Hyperandrogenism; Infertility; Insulin Resista | 2008 |
Insulin-lowering medications in polycystic ovary syndrome.
Topics: Diazoxide; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistanc | 2000 |
Induction of ovulation in infertile women with hyperandrogenism and insulin resistance.
Topics: Acanthosis Nigricans; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Infertility, Female; In | 2000 |
Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects.
Topics: Endocrine System; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Menstrual | 2001 |
Polycystic ovary syndrome in adolescents.
Topics: Adolescent; Anovulation; Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; Glucose Intoler | 2002 |
52 trials available for metformin and Hyperandrogenism
| Article | Year |
|---|---|
Hyperandrogenism and menstrual imbalance are the best predictors of metformin response in PCOS patients.
Topics: Adult; Biomarkers, Pharmacological; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Ag | 2022 |
Maternal serum levels of prokineticin-1 related to pregnancy complications and metformin use in women with polycystic ovary syndrome: a post hoc analysis of two prospective, randomised, placebo-controlled trials.
Topics: Female; Gastrointestinal Hormones; Humans; Hyperandrogenism; Hypoglycemic Agents; Infant, Newborn; M | 2023 |
Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS.
Topics: Adolescent; Adult; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hyperandrogenism; Indi | 2020 |
Sustained Maternal Hyperandrogenism During PCOS Pregnancy Reduced by Metformin in Non-obese Women Carrying a Male Fetus.
Topics: Adult; Androgens; Body Mass Index; Female; Fetal Blood; Fetus; Humans; Hyperandrogenism; Male; Metfo | 2020 |
In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.
Topics: Adult; Androstenedione; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Female; Hirsutism; | 2014 |
Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androsterone; Diabetes Complications; Diabetes Mell | 2013 |
Metformin induces a prompt decrease in LH-stimulated testosterone response in women with PCOS independent of its insulin-sensitizing effects.
Topics: Adrenal Cortex; Adult; Body Mass Index; Double-Blind Method; Female; Follow-Up Studies; Humans; Hype | 2014 |
Impact of metformin on anti-Müllerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial.
Topics: Adolescent; Adult; Anti-Mullerian Hormone; Body Mass Index; Cohort Studies; Cross-Over Studies; Doub | 2015 |
Effects of ethinylestradiol-cyproterone acetate vs. pioglitazone-flutamide-metformin on plasma FGF21 levels in adolescent girls with androgen excess.
Topics: Adolescent; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Fibroblast Growth Fac | 2016 |
The effect of alfacalcidiol and metformin on phenotype manifestations in women with polycystic ovary syndrome - a preliminary study.
Topics: Adult; Female; Humans; Hydroxycholecalciferols; Hyperandrogenism; Hypoglycemic Agents; Insulin Resis | 2016 |
Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome.
Topics: Biomarkers; Cannabinoid Receptor Antagonists; Cytokines; Female; Humans; Hyperandrogenism; Inflammat | 2017 |
Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
Topics: Adult; Anti-Obesity Agents; Body Mass Index; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2009 |
Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Topics: Adult; Contraceptives, Oral, Combined; Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estra | 2008 |
Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Topics: Adult; Arginine; Biomarkers; Blood Glucose; C-Reactive Protein; Contraceptives, Oral, Combined; Cont | 2010 |
Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Clomiphene; Double-Blind Method; Drug Resistance; | 2009 |
Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial.
Topics: Adult; Cardiovascular Diseases; Dehydroepiandrosterone Sulfate; Drug Therapy, Combination; Female; H | 2009 |
Divergent effects of ethinylestradiol-drospirenone and flutamide-metformin on follistatin in adolescents and women with hyperinsulinemic androgen excess.
Topics: Adolescent; Androgen Antagonists; Androstenes; Body Composition; Contraceptives, Oral, Hormonal; Eth | 2011 |
Efficacy of metformin therapy in adolescent girls with androgen excess: relation to sex hormone-binding globulin and androgen receptor polymorphisms.
Topics: Adolescent; Androgens; Biomarkers, Pharmacological; Child; Female; Humans; Hyperandrogenism; Hypogly | 2010 |
The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
Topics: Adolescent; Adult; Androgen Antagonists; Androstenes; Anti-Mullerian Hormone; Blood Glucose; Body Ma | 2011 |
Responsiveness to metformin in girls with androgen excess: collective influence of genetic polymorphisms.
Topics: Adolescent; Androgens; Child; Female; Follow-Up Studies; Humans; Hyperandrogenism; Longitudinal Stud | 2011 |
Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess.
Topics: Adolescent; Androgen Antagonists; Biomarkers; Body Mass Index; Child; Contraceptives, Oral, Combined | 2011 |
Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence.
Topics: Adolescent; Child; Female; Follow-Up Studies; Hirsutism; Humans; Hyperandrogenism; Hypoglycemic Agen | 2011 |
Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome.
Topics: Acetylcysteine; Adolescent; Adult; Anticholesteremic Agents; Antioxidants; Body Mass Index; Female; | 2011 |
Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment.
Topics: Adult; C-Reactive Protein; Drug Therapy, Combination; Female; Hirsutism; Humans; Hydroxymethylglutar | 2011 |
Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin.
Topics: Abdominal Fat; Adolescent; Androgen Antagonists; Body Composition; Cyproterone Acetate; Drug Combina | 2011 |
Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study.
Topics: Adrenal Glands; Adult; Androstenedione; Atorvastatin; Dehydroepiandrosterone; Dehydroepiandrosterone | 2012 |
Therapeutic effects of calcium & vitamin D supplementation in women with PCOS.
Topics: Adult; Calcium; Case-Control Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; | 2012 |
Ethinyl estradiol-cyproterone acetate versus low-dose pioglitazone-flutamide-metformin for adolescent girls with androgen excess: divergent effects on CD163, TWEAK receptor, ANGPTL4, and LEPTIN expression in subcutaneous adipose tissue.
Topics: Abdominal Fat; Adolescent; Androgen Antagonists; Angiopoietin-Like Protein 4; Angiopoietins; Antigen | 2012 |
Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
Topics: Adolescent; Adult; Androstenedione; Apolipoprotein A-I; Apolipoproteins B; Body Constitution; Body M | 2002 |
Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cohort Studies; Contraceptives, Oral; Dose-Response Relationship, Drug; | 2003 |
Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Topics: Acne Vulgaris; Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Fa | 2003 |
Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism.
Topics: Adipose Tissue; Androgen Antagonists; Child; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2003 |
Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception.
Topics: Abdomen; Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Body Composition; Contraceptive Ag | 2003 |
Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Topics: Adiponectin; Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Androstenes; Drug Therapy, Com | 2004 |
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide.
Topics: Adiponectin; Adolescent; Androstenes; Arteriosclerosis; Drug Therapy, Combination; Ethinyl Estradiol | 2004 |
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy.
Topics: Adolescent; Adult; Androstenes; Arteriosclerosis; Drug Therapy, Combination; Ethinyl Estradiol; Fema | 2005 |
Does metformin induce ovulation in normoandrogenic anovulatory women?
Topics: Adult; Drug Administration Schedule; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin; | 2004 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception.
Topics: Adolescent; Adult; Androgen Antagonists; Child; Contraceptives, Oral; Drug Therapy, Combination; Fem | 2005 |
Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-alpha and the neutrophil/lymphocyte ratio.
Topics: Administration, Cutaneous; Adolescent; Adult; C-Reactive Protein; Contraceptive Agents, Female; Cont | 2006 |
Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Dehydroepiandrosterone Sulfate; Female; Humans; Hyperandrogenism; Hypoglycem | 2006 |
Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess.
Topics: Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Body Composition; Body Mass Index; Carotid | 2007 |
Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Topics: Adolescent; Adult; Amenorrhea; Female; Glucose Tolerance Test; Humans; Hyperandrogenism; Hyperinsuli | 2007 |
Flutamide metformin for post-menarcheal girls with preclinical ovarian androgen excess: evidence for differential response by androgen receptor genotype.
Topics: Adolescent; Age Factors; Child; Cross-Over Studies; Drug Therapy, Combination; Female; Flutamide; Ge | 2007 |
Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin.
Topics: Adiponectin; Adolescent; Adult; Double-Blind Method; Female; Flutamide; Humans; Hyperandrogenism; Hy | 2008 |
A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study.
Topics: Adult; Female; Humans; Hyperandrogenism; Insulin Resistance; Metformin; Piperidines; Polycystic Ovar | 2008 |
Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Blood Glucose; Female; Humans; Hydroxyprogesterones | 1996 |
Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome.
Topics: Adult; Androstenedione; Blood Glucose; Female; Glucose Clamp Technique; Humans; Hyperandrogenism; Hy | 1998 |
Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.
Topics: Administration, Oral; Adult; Fasting; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemi | 2000 |
Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche.
Topics: Adolescent; Adult; Blood Glucose; Female; Hirsutism; Hormones; Humans; Hyperandrogenism; Hyperinsuli | 2000 |
Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism.
Topics: Adolescent; Adult; Androgens; Anovulation; Estradiol; Female; Follicle Stimulating Hormone; Humans; | 2001 |
Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation.
Topics: Adult; Androgen Antagonists; Anovulation; Drug Combinations; Female; Flutamide; Humans; Hyperandroge | 2002 |
51 other studies available for metformin and Hyperandrogenism
| Article | Year |
|---|---|
At the crossroads of fertility and metabolism: the importance of AMPK-dependent signaling in female infertility associated with hyperandrogenism.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Mullerian Hormone; Biological Phenomena; Female; Fertil | 2022 |
Polycystic Ovary Syndrome in Adolescence: Challenges in Diagnosis and Management.
Topics: Adolescent; Female; Humans; Hyperandrogenism; Life Style; Menstruation Disturbances; Metformin; Poly | 2022 |
[PCOS - desire for children and pregnancy].
Topics: Anovulation; Child; Female; Humans; Hyperandrogenism; Life Style; Metformin; Polycystic Ovary Syndro | 2023 |
An evaluation of the available pharmacotherapy for the treatment of hirsutism.
Topics: Androgen Antagonists; Female; Hair; Hirsutism; Humans; Hyperandrogenism; Male; Metformin | 2023 |
Decreased Circulating MANF in Women with PCOS is Elevated by Metformin Therapy and is Inversely Correlated with Insulin Resistance and Hyperandrogenism.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Glucose Tolerance Test; Humans; Hyperandrogen | 2020 |
Hyperandrogenism, insulin resistance and acanthosis nigricans (HAIR-AN syndrome): an extreme subphenotype of polycystic ovary syndrome.
Topics: Acanthosis Nigricans; Child; Contraceptives, Oral, Hormonal; Female; Humans; Hyperandrogenism; Insul | 2020 |
Nicotinamide and its metabolite N1-Methylnicotinamide alleviate endocrine and metabolic abnormalities in adipose and ovarian tissues in rat model of Polycystic Ovary Syndrome.
Topics: Adipose Tissue; AMP-Activated Protein Kinases; Animals; Cytokines; Estrous Cycle; Female; Gene Expre | 2020 |
Metformin Ameliorates Uterine Defects in a Rat Model of Polycystic Ovary Syndrome.
Topics: Animals; Chorionic Gonadotropin; Disease Models, Animal; Embryo Implantation; Estradiol; Estrous Cyc | 2017 |
Progesterone Suppression of Luteinizing Hormone Pulse Frequency in Adolescent Girls With Hyperandrogenism: Effects of Metformin.
Topics: Adolescent; Feedback, Physiological; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Hype | 2018 |
Exercise and reproductive function in polycystic ovary syndrome: protocol of a systematic review.
Topics: Diet; Exercise; Female; Fertility; Humans; Hyperandrogenism; Insulin Resistance; Menstrual Cycle; Me | 2017 |
Metformin in Adolescent PCOS: The Way Forward.
Topics: Adolescent; Adult; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Metformin; Polycystic Ovar | 2017 |
Insulin Sensitizers Modulate GnRH Receptor Expression in PCOS Rats.
Topics: Animals; Body Weight; Carboxymethylcellulose Sodium; Diet, High-Fat; Female; Glucose Tolerance Test; | 2018 |
Association between CD16
Topics: Adult; Biomarkers; Case-Control Studies; China; Cross-Sectional Studies; Cyproterone Acetate; Drug C | 2019 |
Effects of in utero androgen excess and metformin treatment on hepatic functions.
Topics: Animals; Female; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Lipids; Liver; Liver Dis | 2019 |
Effect of metformin on clinical and biochemical hyperandrogenism in adolescent girls with type 1 diabetes.
Topics: Adolescent; Adult; Biomarkers; Child; Diabetes Mellitus, Type 1; Female; Follow-Up Studies; Humans; | 2019 |
Metformin for polycystic ovary syndrome.
Topics: Algorithms; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Metformin; Off-Label Use; Ovulati | 2013 |
Metformin modulates PI3K and GLUT4 expression and Akt/PKB phosphorylation in human endometrial stromal cells after stimulation with androgen and insulin.
Topics: Adult; Androgens; Cells, Cultured; Endometrium; Extracellular Signal-Regulated MAP Kinases; Female; | 2014 |
Hyperinsulinaemic androgen excess in adolescent girls.
Topics: Adolescent; Androgens; Drug Therapy, Combination; Dyslipidemias; Female; Flutamide; Hirsutism; Human | 2014 |
European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group's Questionnaire.
Topics: Adult; Androgens; Biomarkers; Clomiphene; Contraceptives, Oral; Diagnosis, Differential; Endocrinolo | 2014 |
The effect of metformin on androgen production in diabetic women with non-classic congenital adrenal hyperplasia.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Hyperplasia, Congenital; Adult; Androgens; Blood Glucose; Dehy | 2014 |
Polycystic ovaries and obesity.
Topics: Adipokines; Adiponectin; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Inf | 2015 |
Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes.
Topics: Adolescent; Adult; Androgen Antagonists; China; Cyproterone Acetate; Drug Combinations; Drug Therapy | 2015 |
Hyperandrogenism and Insulin Resistance, Not Changes in Body Weight, Mediate the Development of Endothelial Dysfunction in a Female Rat Model of Polycystic Ovary Syndrome (PCOS).
Topics: Androgen Antagonists; Androgens; Animals; Arteries; Blood Pressure; Body Weight; Dihydrotestosterone | 2015 |
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Topics: Adolescent; Alopecia; Androgen Antagonists; Androgens; Anovulation; Diagnostic Techniques, Endocrine | 2015 |
Diagnosis and Treatment of Polycystic Ovary Syndrome.
Topics: Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperandrogenism; Hypogl | 2016 |
[Woman 19-old with hirsutism, obesity and acanthosis nigricans].
Topics: Acanthosis Nigricans; Female; Hirsutism; Humans; Hyperandrogenism; Insulin Resistance; Metformin; Ob | 2016 |
Effect of DHEA and metformin on corpus luteum in mice.
Topics: Animals; Corpus Luteum; Dehydroepiandrosterone; Dinoprost; Female; Hyperandrogenism; Hypoglycemic Ag | 2009 |
Androgen excess in women: not just a cosmetic problem.
Topics: Adrenal Hyperplasia, Congenital; Androgen Antagonists; Androgens; Female; Hirsutism; Humans; Hyperan | 2010 |
[Diagnosis and treatment of polycystic ovary syndrome].
Topics: Acne Vulgaris; Alopecia; Amenorrhea; Androgens; Clomiphene; Diabetes Complications; Diagnosis, Diffe | 2010 |
A single nucleotide polymorphism in STK11 influences insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess.
Topics: AMP-Activated Protein Kinase Kinases; Child; Drug Resistance; Female; Genotype; Humans; Hyperandroge | 2010 |
Link between metformin and the peroxisome proliferator-activated receptor γ pathway in the uterine tissue of hyperandrogenized prepubertal mice.
Topics: Animals; Arachidonate 12-Lipoxygenase; Arachidonate 15-Lipoxygenase; Dehydroepiandrosterone; Disease | 2011 |
Latin American consensus: children born small for gestational age.
Topics: Child, Preschool; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female | 2011 |
Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular mass of their daughters.
Topics: Adult; Anti-Mullerian Hormone; Birth Weight; Diabetes, Gestational; Female; Fertility Agents, Female | 2012 |
Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance.
Topics: Adult; Blood Glucose; Body Mass Index; Drug Combinations; Female; Fluorobenzenes; Follow-Up Studies; | 2012 |
Severe hyperandrogenemia and insulin resistance in a 12-year-old girl.
Topics: Child; Estrogens; Ethinyl Estradiol; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic | 2012 |
Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Anti-Mullerian Hormone; Female; Follicular Phase; H | 2013 |
Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism.
Topics: Abdomen; Adolescent; Anovulation; Body Composition; Female; Humans; Hyperandrogenism; Hyperlipidemia | 2002 |
[Hirsutism].
Topics: Adolescent; Adrenal Hyperplasia, Congenital; Adult; Androgen Antagonists; Anti-Inflammatory Agents; | 2003 |
Hyperandrogenism and the skin.
Topics: Acne Vulgaris; Adrenal Hyperplasia, Congenital; Female; Humans; Hyperandrogenism; Male; Metformin; P | 2004 |
Surgical treatment of polycystic ovary syndrome associated with infertility.
Topics: Clomiphene; Female; Gonadotropins; Gynecologic Surgical Procedures; Humans; Hyperandrogenism; Infert | 2004 |
Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in nonobese adolescents and women.
Topics: Adolescent; Adult; Androgen Antagonists; Dose-Response Relationship, Drug; Drug Therapy, Combination | 2006 |
The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice.
Topics: Adjuvants, Immunologic; Administration, Oral; AMP-Activated Protein Kinases; Animals; Catalase; Cycl | 2006 |
Metformin prevents embryonic resorption induced by hyperandrogenisation with dehydroepiandrosterone in mice.
Topics: Animals; Blood Glucose; CD4-CD8 Ratio; Dehydroepiandrosterone; Estradiol; Female; Fetal Resorption; | 2006 |
Pharmacologic therapy of polycystic ovary syndrome.
Topics: Amenorrhea; Contraceptives, Oral, Hormonal; Drug Therapy, Combination; Female; Humans; Hyperandrogen | 2007 |
Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adrenal Glands; Adult; Aged; Antipsychotic Agents; Cortodo | 2007 |
The investigation and management of severe hyperandrogenism pre- and postmenopause: non-tumor disease is strongly associated with metabolic syndrome and typically responds to insulin-sensitization with metformin.
Topics: Adult; Cohort Studies; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Metabolic Syndrome; Me | 2008 |
Insulin and the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Female; Humans; Hydroxyprogesterones; Hyperandrogenism; Insulin; Lutei | 1996 |
[Effects of metformin on insulin resistance in obese and hyperandrogenic women].
Topics: Adult; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity | 1997 |
Administration of metformin to a diabetic woman with extreme hyperandrogenemia of nontumoral origin: management of infertility and prevention of inadvertent masculinization of a female fetus.
Topics: Adult; Diabetes Mellitus, Type 1; Disorders of Sex Development; Female; Humans; Hyperandrogenism; Hy | 1999 |
Effects of metformin on androgens and insulin concentrations in type A insulin resistance syndrome.
Topics: Acanthosis Nigricans; Adolescent; Androgens; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypo | 2000 |
[Study on treatment of hyperandrogenism and hyperinsulinism in polycystic ovary syndrome with Chinese herbal formula "tiangui fang"].
Topics: Adolescent; Adult; Drugs, Chinese Herbal; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypogly | 2000 |